KR20110025168A - 약학적 조성물 - Google Patents

약학적 조성물 Download PDF

Info

Publication number
KR20110025168A
KR20110025168A KR1020107024775A KR20107024775A KR20110025168A KR 20110025168 A KR20110025168 A KR 20110025168A KR 1020107024775 A KR1020107024775 A KR 1020107024775A KR 20107024775 A KR20107024775 A KR 20107024775A KR 20110025168 A KR20110025168 A KR 20110025168A
Authority
KR
South Korea
Prior art keywords
modulator
complex
enzyme
pdh
cells
Prior art date
Application number
KR1020107024775A
Other languages
English (en)
Korean (ko)
Inventor
로버트 쇼어
로버트 로드리게즈
폴 빙함
락말 더블유. 보테주
주자나 자칼
Original Assignee
로버트 쇼어
로버트 로드리게즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로버트 쇼어, 로버트 로드리게즈 filed Critical 로버트 쇼어
Publication of KR20110025168A publication Critical patent/KR20110025168A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020107024775A 2008-04-04 2008-04-04 약학적 조성물 KR20110025168A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/004410 WO2009123597A1 (en) 2008-04-04 2008-04-04 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
KR20110025168A true KR20110025168A (ko) 2011-03-09

Family

ID=41135840

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107024775A KR20110025168A (ko) 2008-04-04 2008-04-04 약학적 조성물

Country Status (10)

Country Link
EP (1) EP2268278A4 (es)
JP (1) JP2011516473A (es)
KR (1) KR20110025168A (es)
CN (1) CN102056605A (es)
AU (1) AU2008354009A1 (es)
BR (1) BRPI0821894A2 (es)
CA (1) CA2720396A1 (es)
IL (1) IL208387A0 (es)
MX (1) MX2010010867A (es)
WO (1) WO2009123597A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX343847B (es) 2010-07-08 2016-11-24 Wrigley W M Jun Co Goma de mascar que contiene una base de goma de matriz de gelatina reticulada.
US9421234B2 (en) * 2011-05-20 2016-08-23 Nutramax Laboratories, Inc. Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration
CA2863600A1 (en) * 2012-02-16 2013-08-22 The Penn State Research Foundation Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof
CN105142643B (zh) * 2012-12-19 2021-09-03 基石医药公司 药物化合物
AU2014398232B2 (en) 2014-06-19 2019-11-28 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
WO2015195071A1 (en) 2014-06-19 2015-12-23 Robert Shorr Pharmaceutical compounds
CN110590624B (zh) * 2019-09-26 2021-02-26 苏州富士莱医药股份有限公司 一种硫辛酸衍生物8-(乙基二硫基)-6-(苯基二硫基)辛酸的制备方法
WO2023012305A1 (en) * 2021-08-04 2023-02-09 Cytacoat Ab Disulfide compounds as medicaments

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2853497A (en) * 1953-12-04 1958-09-23 Merck & Co Inc 6, 8-bis (hydrocarbon substituted mercapto) 5-hydroxycaprylic acids and delta-lactones thereof
US2789991A (en) * 1954-05-20 1957-04-23 American Cyanamid Co Substituted disulfones
JPS61198148A (ja) * 1985-01-29 1986-09-02 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
GB9618934D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
DK1624060T3 (da) * 1998-03-20 2012-04-10 Commw Scient Ind Res Org Kontrol af genekspression
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
US6331559B1 (en) * 1998-10-26 2001-12-18 The Research Foundation Of State University Of New York At Stony Brook Lipoic acid derivatives and their use in treatment of disease
DE19904794A1 (de) * 1999-02-05 2000-08-10 Biotechnolog Forschung Gmbh Verfahren zur Verbesserung des Primärstoffwechsels von Säugerzelllinien
US6284786B1 (en) * 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
IT1312060B1 (it) * 1999-04-09 2002-04-04 Antibioticos Spa Uso dell'acido alfa lipoico nel trattamento antimetastatico.
US7108977B2 (en) * 2000-05-19 2006-09-19 Hoffmann-La Roche Inc. Process for determining the tumoricidal potential of a sample the use of a nucleic acid which is downregulated in human tumor cells
WO2006119355A2 (en) * 2005-05-03 2006-11-09 Albert Einstein College Of Medicine Of Yeshiva University Mammalian hypothalamic nutrient modulation of glucose metabolism
US20070077583A1 (en) * 2005-09-21 2007-04-05 Aurelium Biopharma, Inc. Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
JP5412423B2 (ja) * 2007-04-18 2014-02-12 コーナーストーン ファーマシューティカルズ，インコーポレーテッド リポ酸誘導体
AU2008242827B2 (en) * 2007-04-18 2014-06-05 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
BRPI0821176A2 (pt) * 2008-03-04 2015-10-06 Robert Rodriguez modulador do estado de fosforilação de pelo menos um complexo de enzimas, método para modular o complexo de pdh em um paciente que apresenta uma doença, condição, ou síndrome e método pra diagnosticar e predizer benefício em um paciente que apresenta sintomas de uma doença, condição, ou síndrome causada por uma alteração da estrutura e/ou da atividade do complexo de pdh

Also Published As

Publication number Publication date
EP2268278A4 (en) 2011-11-09
BRPI0821894A2 (pt) 2015-07-21
AU2008354009A1 (en) 2009-10-08
WO2009123597A1 (en) 2009-10-08
EP2268278A1 (en) 2011-01-05
JP2011516473A (ja) 2011-05-26
CN102056605A (zh) 2011-05-11
MX2010010867A (es) 2011-05-25
CA2720396A1 (en) 2009-10-08
IL208387A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
US8552050B2 (en) Activators of pyruvate kinase M2 and methods of treating disease
KR20110025168A (ko) 약학적 조성물
Daurio et al. AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor–Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment
US8969313B2 (en) Methods and compounds for preventing and treating a tumour
ES2663789T3 (es) Compuesto de pirazol-amida y usos medicinales del mismo
US20090291857A1 (en) Methods to identify inhibitors of the unfolded protein response
Hebert-Chatelain et al. Preservation of NADH ubiquinone-oxidoreductase activity by Src kinase-mediated phosphorylation of NDUFB10
Tomczyk et al. Mitochondrial sirtuin-3 (SIRT3) prevents doxorubicin-induced dilated cardiomyopathy by modulating protein acetylation and oxidative stress
CA2665380A1 (en) Treatment of insulin resistance and disorders associated therewith
Guerra et al. Protein kinase CK2 inhibition is associated with the destabilization of HIF-1α in human cancer cells
Xu et al. The SIRT2/cMYC pathway inhibits peroxidation-related apoptosis in cholangiocarcinoma through metabolic reprogramming
Ferretta et al. New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations
CN103860529B (zh) 金色灰绿曲霉素类化合物的用途
KR102381684B1 (ko) 피부암 치료
US20150266842A1 (en) Methods and compositions related to a retinoid receptor-selective pathway
JP2011513395A (ja) 酵素の構造、活性、及び／又は、発現レベルの調節
Li et al. Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations
Dinkova-Kostova et al. Electrophilic metabolites targeting the KEAP1/NRF2 partnership
CN113194942A (zh) 用于抑制和/或治疗生长相关疾病和/或其临床病症的组合物和方法
US20210267939A1 (en) Compositions and methods for treating nafld/nash and related disease phenotypes
US11137400B2 (en) Methods for predicting and determining responsiveness to activators of JNK kinase
WO2010033958A1 (en) Nuclear factor kappa b pathway inhibitor composition and use of same
CN112870358A (zh) 去泛素化酶usp20在降低胆固醇合成并改善代谢综合征中的用途
Han Roles of PKC isozymes in retinoic acid-induced B16 mouse melanoma cell growth inhibition and differentiation

Legal Events

Date Code Title Description
A201 Request for examination
E601 Decision to refuse application